LLY

1,007.62

+0.79%↑

JNJ

231.19

+1.11%↑

UNH

399.28

+0.45%↑

AZN

185.56

-0.13%↓

NVS

149.72

+0.08%↑

LLY

1,007.62

+0.79%↑

JNJ

231.19

+1.11%↑

UNH

399.28

+0.45%↑

AZN

185.56

-0.13%↓

NVS

149.72

+0.08%↑

LLY

1,007.62

+0.79%↑

JNJ

231.19

+1.11%↑

UNH

399.28

+0.45%↑

AZN

185.56

-0.13%↓

NVS

149.72

+0.08%↑

LLY

1,007.62

+0.79%↑

JNJ

231.19

+1.11%↑

UNH

399.28

+0.45%↑

AZN

185.56

-0.13%↓

NVS

149.72

+0.08%↑

LLY

1,007.62

+0.79%↑

JNJ

231.19

+1.11%↑

UNH

399.28

+0.45%↑

AZN

185.56

-0.13%↓

NVS

149.72

+0.08%↑

Home・Listă Acțiuni・AbbVie Inc

AbbVie Inc

Deschisă

SectorSănătate

212.17 3.1

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

204.18

Maxim

212.12

Indicatori cheie
By Trading Economics
Venit	-1.1B 697M
Vânzări	-1.6B 15B
P/E Medie Sector	99.402 51.415
EPS	2.65
Randament dividend	3.34
Marjă de profit	4.646
Angajați	57,000
EBITDA	-635M 4.7B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+22.17% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	3.34% 2.34%
Următoarele câștiguri	30 iul. 2026
Data viitoare de dividende	15 mai 2026
Următoarea dată ex-dividende	14 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	9.2B 358B
Deschiderea anterioară	209.07
Închiderea anterioară	212.17

Sentimentul știrilor

By Acuity

25%

75%

59 / 346 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

180.37 / 195.54 Suport & Rezistență

AbbVie Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2026, 12:38 UTC

Câștiguri

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

4 feb. 2026, 13:20 UTC

Câștiguri

AbbVie 4Q Revenue Rises on Immunology Growth

29 apr. 2026, 12:41 UTC

Câștiguri

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

29 apr. 2026, 12:23 UTC

Câștiguri

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

29 apr. 2026, 11:50 UTC

Câștiguri

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

29 apr. 2026, 11:49 UTC

Câștiguri

AbbVie 1Q Global Humira Rev $688 M >ABBV

29 apr. 2026, 11:48 UTC

Câștiguri

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie 1Q EPS 39c >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie 1Q Net $695M >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie 1Q International HUMIRA Rev $331M >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie 1Q Rev $15B >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie 1Q Adj EPS $2.65 >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

29 apr. 2026, 11:47 UTC

Câștiguri

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

4 feb. 2026, 19:38 UTC

Câștiguri

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb. 2026, 16:19 UTC

Câștiguri

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb. 2026, 15:18 UTC

Câștiguri

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb. 2026, 13:18 UTC

Câștiguri

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb. 2026, 12:48 UTC

Câștiguri

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

4 feb. 2026, 12:48 UTC

Câștiguri

AbbVie 4Q Rev $16.62B >ABBV

4 feb. 2026, 12:48 UTC

Câștiguri

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

4 feb. 2026, 12:48 UTC

Câștiguri

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

4 feb. 2026, 12:48 UTC

Câștiguri

AbbVie 4Q Net $1.82B >ABBV

4 feb. 2026, 12:48 UTC

Câștiguri

AbbVie 4Q Adj EPS $2.71 >ABBV

4 feb. 2026, 12:48 UTC

Câștiguri

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

4 feb. 2026, 12:48 UTC

Câștiguri

AbbVie 4Q International HUMIRA Rev $349M >ABBV

4 feb. 2026, 12:48 UTC

Câștiguri

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Comparație

Modificare preț

AbbVie Inc Așteptări

Obiectiv de preț

By TipRanks

22.17% sus

Prognoză pe 12 luni

Medie 253.94 USD 22.17%

Maxim 294 USD

Minim 203 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAbbVie Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 20 analiști care au acordat evaluări ale acțiunilor AbbVie Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

180.37 / 195.54Suport & Rezistență

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

59 / 346 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.